The mechanism is always the same: a study is published, the media reduce its thesis to the bare minimum, and the supplement manufacturer is left asking: are the health claims on my label still legally safe? In the case of creatine, the answer is not straightforward — and it depends on which claims the manufacturer uses, how those claims are substantiated, and whether the supporting scientific documentation keeps pace with the latest literature.
What the study actually found — and why that has legal significance
Research into creatine and tumour cell proliferation has existed in the scientific literature for years. The mechanism attracting researchers' interest concerns the role of creatine as an energy substrate for cells with high metabolic demands — including certain cancer cell lines. This is not equivalent to claiming that creatine consumption by a healthy individual increases the risk of developing cancer. The difference is enormous, but under food law what matters is something else entirely: whether the manufacturer is able to demonstrate that its health claims are consistent with the current state of scientific knowledge.
Article 5(1) of Regulation (EC) No 1924/2006 on nutrition and health claims requires that the use of health claims be based on generally accepted scientific evidence. "Generally accepted" does not mean "unchallenged by any study". It does mean, however, that the manufacturer must monitor the literature and be prepared to demonstrate that new findings do not undermine the basis of its claims. When a controversial study emerges — even one that is methodologically weak — the Polish Chief Sanitary Inspectorate (GIS) or the European Commission may ask: is the manufacturer aware of it, and how does the manufacturer respond to it?
Expert Tip: Manufacturers using health claims from the Annex to Regulation (EU) No 432/2012 (the list of authorised claims) are in a relatively stronger position — those claims were authorised by EFSA. However, authorisation does not exempt a manufacturer from the obligation to monitor the scientific basis. If significant contradictory evidence emerges after authorisation, EFSA may initiate a re-evaluation procedure.
Creatine in the health claims register: what is permitted and what is not
Creatine has authorised health claims. The first, contained in Regulation (EU) No 432/2012, reads: "Creatine increases physical performance in successive bursts of short-term, high intensity exercise" (EFSA Journal 2011;9(7):2303). The second claim, concerning the effect of creatine on muscle strength in persons over 55 engaged in resistance training, was authorised by Regulation (EU) 2017/672 on the basis of EFSA Journal 2016;14(2):4400. A manufacturer that uses exactly these claims in exactly the authorised form has a solid legal basis.
Problems arise when a manufacturer begins to modify the claim — adding phrases such as "supports recovery", "improves body composition", or "supports muscle building" without reference to the specific authorised wording. Such extensions are incompatible with Article 10(1) of Regulation 1924/2006, which prohibits the use of health claims other than those that comply with the requirements of the Regulation and appear on the lists of authorised claims.
- PERMITTED: "Creatine increases physical performance in successive bursts of short-term, high intensity exercise" — in accordance with Regulation (EU) No 432/2012 (second claim on resistance training and muscle strength in persons over 55 — Regulation (EU) 2017/672)
- NOT PERMITTED WITHOUT AUTHORISATION: "Creatine supports muscle mass building", "supports post-workout recovery", "improves body composition"
- ABSOLUTELY PROHIBITED: any claims suggesting properties that prevent or treat cancer — Article 7(3) of Regulation (EU) No 1169/2011 (general prohibition on attributing disease prevention/treatment properties to food) and Article 14 of Regulation (EC) No 1924/2006 (disease risk reduction claims requiring separate authorisation)
The reverse risk: the manufacturer who "corrects" the study on the label
Following the media storm surrounding a study, there is a temptation to "clarify" on the product page or in marketing materials that creatine is safe and does not cause cancer. This reasoning is intuitively sound but legally hazardous. Article 7(3) of Regulation (EU) No 1169/2011 prohibits attributing to food the property of preventing, treating, or curing a human disease, and Article 14 of Regulation (EC) No 1924/2006 requires authorisation for disease risk reduction claims. The statement "creatine does not cause cancer" is a health claim making reference to disease — even though it is expressed in the negative.
The Polish Chief Sanitary Inspectorate (GIS), in administrative decisions issued in the course of inspections, consistently treats negative health claims ("does not cause", "does not increase the risk of", "is safe for persons with X") as requiring authorisation on the same basis as positive claims. The absence of such authorisation constitutes a breach of Article 10(1) of Regulation 1924/2006, which may result in an administrative decision ordering the withdrawal of the product from the market or the removal of the labelling — on the basis of Article 17 of the Act of 25 August 2006 on food and nutrition safety.
Expert Tip: Safe crisis communication by a manufacturer following a controversial study should take place exclusively through PR and educational channels (company blog, press release) — never on the product label or in direct commercial materials accompanying the product. The distinction between a corporate communication and product labelling is one of the few legally permissible spaces for such clarifications.
What GIS examines during an inspection — and why now in particular
GIS inspection practice shows that sanitary inspection authorities respond to media reports about food supplements. This is not an officially designated inspection trigger, but the correlation between major press articles and intensified inspections within a given product category has been observed by the industry for years. Following the wave of headlines about creatine and cancer, manufacturers in this category should treat a documentation review as a proactive measure, not a reactive one.
- Quality documentation: raw material specification, certificates of analysis (CoA) — GIS verifies the creatine content declared on the label
- Basis for health claims: whether the claim appears in Regulation (EU) No 432/2012 and whether the wording on the label matches the authorised version
- Labelling: information required under Article 6 of Regulation (EU) No 1169/2011, including the recommended daily serving and a warning against exceeding it
- Notification to GIS: whether the product was notified in accordance with Article 29 of the Act on food and nutrition safety prior to being placed on the market
- Marketing materials: website content, social media — GIS has the authority to inspect these as part of labelling in the broad sense
graph TD
A[Publication of scientific study] --> B{Does the study suggest a safety risk?}
B -->|Yes| C[European Commission may request a scientific opinion from EFSA]
B -->|No / inconclusive results| D[Study enters the scientific literature database]
C --> E[EFSA: expedited assessment procedure]
E --> F{Outcome of EFSA assessment}
F -->|Risk confirmed| G[Suspension / withdrawal of claim authorisation]
F -->|Risk not confirmed| H[Status quo — claim remains valid]
D --> I[Media oversimplify the study findings]
I --> J[Intensified GIS inspections in the product category]
J --> K{Is the manufacturer's documentation complete?}
K -->|Yes| L[Inspection concludes without an enforcement decision]
K -->|No| M[Administrative decision ordering a labelling change or product withdrawal]
G --> N[Manufacturer must redesign label and communications]
When a scientific study can trigger a procedure at EU level
If a study indicates a potential safety risk associated with a substance present in food supplements, the European Commission may — on the basis of Article 8 of Regulation (EC) No 178/2002 — apply precautionary measures and request an urgent scientific opinion from EFSA. EFSA then has an expedited risk assessment procedure available. Creatine, as a widely used substance that has been assessed by EFSA on multiple occasions, is an unlikely candidate for such a procedure on the basis of a single animal model study. But the mechanism exists, and it is worth understanding how it operates.
The realistic scenario is different: the study enters the scientific database, and EFSA takes it into account in any future review of authorised health claims relating to creatine. If the scientific literature begins to consistently suggest a risk mechanism, EFSA may initiate a re-evaluation of the claim on its own initiative — which in practice means the suspension of its use pending the outcome of the procedure. A manufacturer that has built its entire marketing communication around that single claim is then left with a label to redesign.
Expert Tip: Diversifying the marketing basis of a product — replacing reliance on a single health claim with communication focused on composition, raw material quality, and transparency — reduces dependence on the regulatory status of any particular claim. This is not an alternative to compliance, but a complement to the overall strategy.
What manufacturers should do within the next 30 days
A media controversy is the moment at which a manufacturer's documentation should be ready for inspection — not still being prepared. Practical steps are as follows: first, review all health claims used on the label, website, and advertising materials for compliance with Regulation (EU) No 432/2012. Second, verify that the wording of the claims corresponds literally to the authorised version — any deviation represents a risk. Third, review digital communication content for disease-related claims (including negative ones).
- Label audit: compare every claim against the wording in Regulation (EU) No 432/2012 — literally, not "approximately"
- Website and social media audit: health claims on a website are subject to the same rules as those on a label
- Check the GIS notification: if the product's composition or name has changed, the notification may need to be updated
- Prepare a scientific documentation file: a list of the studies underpinning your claims, with the date of the most recent update
- Consult a lawyer on crisis communication before publication — not after
Has your health claims documentation not been reviewed in over a year? That is precisely how long it takes for GIS to come knocking.
Frequently Asked Questions
Can a single scientific study result in my product being withdrawn from the market?
Not directly. A single study does not automatically trigger a product withdrawal procedure. However, if the study indicates a safety risk, the European Commission may, on the basis of Article 8 of Regulation (EC) No 178/2002, apply precautionary measures and commission EFSA to carry out a re-evaluation. In practice, product withdrawal from the market by GIS follows an administrative decision finding a breach of the applicable rules — for example, the use of an unauthorised health claim or failure to notify GIS — rather than the mere existence of a controversial study.
Can I state on my product page that the study on creatine and cancer was misrepresented by the media?
On a website — yes, as part of educational and PR communication, provided the content does not contain health claims. On the product label or in commercial materials directly associated with the product — no, because any reference to cancer (even in the form of a negation) constitutes a health claim making reference to disease within the meaning of Article 7(3) of Regulation (EU) No 1169/2011, and requires authorisation under Article 14 of Regulation (EC) No 1924/2006, which does not currently exist for such a claim.
Which health claims relating to creatine are legally permitted in Poland?
Creatine appears in Regulation (EU) No 432/2012 with an authorised health claim: "Creatine increases physical performance in successive bursts of short-term, high intensity exercise". A second claim, concerning resistance training and muscle strength in persons over 55, was authorised by Regulation (EU) 2017/672. Manufacturers must use these claims in wording that corresponds to the authorised version — any stylistic or substantive deviation constitutes a breach of Article 10(1) of Regulation 1924/2006. Claims such as "builds muscle mass" or "supports recovery" are not authorised and may not be used.
What are the consequences for a manufacturer of using an unauthorised health claim?
GIS may issue an administrative decision ordering the manufacturer to cease using the claim, to amend the labelling, or — in extreme cases — to withdraw the product from the market. The legal basis is Article 17 of the Act of 25 August 2006 on food and nutrition safety, read in conjunction with Article 10 of Regulation 1924/2006. In addition, the manufacturer is exposed to proceedings under Article 100 of the Act on food and nutrition safety, which provides for financial penalties. The costs of withdrawing a product and redesigning its label may far exceed the cost of a prior legal audit.
Does a notification submitted to GIS when placing a product on the market protect me during an inspection?
A notification submitted in accordance with Article 29 of the Act on food and nutrition safety is a necessary but not sufficient condition. During an inspection, GIS verifies whether the current composition, name, and labelling of the product are consistent with what was notified. If, after submitting the notification, the manufacturer changed the composition or added new health claims without updating the notification, the inspection may result in an enforcement administrative decision regardless of the fact that an earlier notification was filed.
Do animal model studies carry the same legal weight as clinical trials in humans when health claims are being assessed?
No. EFSA's guidelines on the evaluation of health claims (EFSA Journal 2011;9(7):2303) explicitly state that animal model studies and in vitro studies carry lower evidential value than randomised controlled clinical trials in humans. A single mouse study is not a sufficient basis for overturning a claim authorised by EFSA on the basis of the totality of the scientific literature. However, as part of a growing body of evidence, it may influence future EFSA determinations.
Do I need to update my product's scientific documentation after every new study concerning an ingredient?
The regulations do not specify how frequently documentation must be updated. Article 5(1) of Regulation 1924/2006 does require, however, that claims be based on generally accepted scientific evidence — which is a dynamic standard. In practice, an annual scientific documentation audit for active ingredients, supplemented by ad hoc reviews following the publication of significant studies, represents the minimum necessary to demonstrate due diligence during a GIS inspection.